HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Cancer cells often undergo significant metabolic reprogramming to sustain rapid growth and survive in hostile tumor microenvironments. One of the most prominent changes is the shift to glycolysis, even when oxygen is available, known as the Warburg effect. This alteration allows cancer cells to generate the necessary energy and biosynthetic materials for uncontrolled proliferation. Targeting these metabolic pathways has become a key strategy in cancer research, with the goal of depriving tumors of the resources they need to grow. Researchers are developing drugs that can block critical enzymes or transporters involved in these metabolic shifts, offering a potential avenue for new, more effective cancer treatments.
